Clinicians may be able to more accurately determine whether breast cancer will recur in patients taking tamoxifen by genotyping their cytochrome P450 2D6 gene, if research published in the Dec. 20 issue of The Journal of Clinical Oncology can be further verified and exploited by the molecular diagnostics field.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.